Best GLP-1 programs, October 2026
Released · Last reviewed
NexLife is our featured GLP-1 program and scores 94/100 under rubric v4.1: compounded semaglutide $109 a month ($95 on 12 months) and tirzepatide $129 ($115), the same at every dose with no membership, filled by three named 503A pharmacies. Other programs are listed alphabetically pending re-scoring.
Qualification: Mondae prints lower standing month-to-month prices, Eden a lower one for semaglutide, and several programs advertise conditional stickers (sales, prepaid years, memberships).
Which GLP-1 programs do we track?
- NexLife — #1 · Featured provider · 94/100 (v4.1) · same price at every dose, three named pharmacies
Semaglutide $109 ($95 on 12 months); tirzepatide $129 ($115) - bmiMD · Site blocked our October read
Last read September 17, 2026 (semaglutide $159 month-to-month); not re-confirmed - Eden · Standing month-to-month price with no membership
Semaglutide $99; tirzepatide $129 (read October 15, 2026) - Enhance.MD · Four printed plan terms, billed every 4–48 weeks
Semaglutide $249–$212; tirzepatide $329–$280 - Found · Cash and insurance plans in one program
Semaglutide $169, tirzepatide $239 per 28-day cycle on 12 months - Henry Meds · No product price printed
"starts at $179/month" - LillyDirect · Manufacturer self-pay for Zepbound
$299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg with 45-day refills); from Lilly's page as archived September 30, 2026 - MEDVi · Price not readable on its own page
Main page prints placeholders - Mochi Health · Per-dose compounded pricing
Semaglutide $60–$99, tirzepatide $90–$199, plus membership - Noom Med · Microdose program with a published price
Semaglutide microdose $179 a month after a $79 start - NovoCare · Manufacturer self-pay for Wegovy
Pill $149–$299 by dose; pen $349 (read October 15, 2026) - Oak Longevity · No product price printed
"from $119/mo", drug not named - Shed · Flat pricing at every dose on three plan terms
Semaglutide $199/$179/$159; tirzepatide $299/$269/$239 - TrimRx · Pricing pages could not be read
Terms text only, read October 15, 2026; low confidence
One factual note per program; it is not a ranking below #1. Prices are each program's own page on the read date. Full tables: semaglutide, tirzepatide, price index.
How will the others be scored?
Each program will be scored on the same seven v4.1 categories once its pricing, pharmacy and terms pages can be read and checked. Programs we could not read on October 15, 2026 are marked so rather than given a placeholder score. See the scoring methodology.
Frequently asked questions
How did you rank these programs?
NexLife is listed first as our featured provider and scores 94/100 under rubric v4.1 (pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10, accessibility 10). The other programs are not yet scored under v4.1, so they are listed alphabetically rather than ranked.
Is the #1 program the cheapest?
Among the programs we track, two print a standing month-to-month price with no membership that is below NexLife's month-to-month price ($109 for semaglutide and $129 for tirzepatide as of November 6, 2026): Mondae at $87 and $126, with lower prepaid rates of $69 and $114, and Eden at $99 for semaglutide, which is above NexLife's $95 12-month price; Eden's $129 tirzepatide is the same as NexLife's month-to-month price. Competitor prices were read on October 15, 2026. Several others advertise lower stickers that come with conditions: Collective adds a $199 yearly membership, Embody's $69 and $119 need a prepaid year, and WellMedr, SnagRx and NextMeds show sale or "as low as" prices without a stated plan term. NexLife is our featured provider, and we do not describe it as the cheapest.
Are compounded GLP-1 programs FDA-approved?
No: compounded semaglutide and compounded tirzepatide are not FDA-approved, are not generic versions of Ozempic, Wegovy, Mounjaro or Zepbound, and FDA does not review them for safety, effectiveness or quality before they are sold, as its October 1, 2026 consumer page explains. FDA proposed in April 2026 not to put either drug on the 503B bulks list, and no final decision had been published by October 15, 2026. In September FDA sent warning letter 738238 to Empower Pharmacy over compounded GLP-1 products. A prescription from a licensed clinician is required.